gsk2981278
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 22, 2015 (NCT02548052)
Timeline
Indications
Studied for
Mechanism of action
- Nuclear receptor ROR-gammaINVERSE AGONIST
RORC inverse agonist
Chemistry & pharmacology
Loading structure…
SMILES
CCc1ccc(N(CC(C)C)S(=O)(=O)c2ccc(OCC3CCOCC3)c(CO)c2)cc1- Mol. weight
- 461.62 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4225088 ↗
Also known as
- gsk2981278
- gsk2981278
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03004846 | Phase 2 | Feb 13, 2017 | GlaxoSmithKline |
| NCT02548052 | Phase 1 | Oct 22, 2015 | GlaxoSmithKline |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 2 | 2 | 2 | 2015 |
1 organizations
Page 1 / 1